The U.S. home infusion therapy market is gaining momentum as patients and healthcare providers increasingly favor treatment at home for conditions that require prolonged infusion therapy. The rising elderly population, growing prevalence of cancer, diabetes, chronic pain, gastrointestinal disorders, cardiovascular diseases, and chronic respiratory diseases are supporting market expansion. Home infusion therapy provides patients with greater convenience and can reduce the need for hospital stays, while also supporting cost-effective care and lowering exposure to hospital-acquired infections. Increasing preference for home-based treatment, improvements in infusion devices, and expanding reimbursement for outpatient and home-based therapies are further strengthening market growth.

Market Size and Growth Forecasts

The U.S. home infusion therapy market was valued at USD 20.42 billion in 2024 and is estimated to reach USD 21.95 billion in 2025. The market is projected to reach USD 39.96 billion by 2033, expanding at a CAGR of 7.78% from 2025 to 2033. The aging population is one of the major factors supporting this growth, as older adults are more susceptible to infections and chronic health conditions requiring extended treatment.

The market is also benefiting from increasing patient preference for receiving therapy in familiar home environments. Home infusion can eliminate or reduce hospital stays while allowing patients to continue daily activities. Government standards, healthcare provider policies, and reimbursement frameworks are also influencing adoption. The regulatory environment is primarily shaped by CMS for care and reimbursement requirements, while the FDA regulates infusion devices and related software for safety and efficacy.

Download a free sample copy of the U.S. Home Infusion Therapy market report to understand detailed coverage and inclusions in the final report

Key Technologies

Technology is playing an important role in improving the safety, efficiency, and convenience of home infusion therapy. Modern infusion pumps can provide controlled delivery of medications, nutrition, and fluids while incorporating alert systems that help reduce risks associated with incorrect pump settings or potential adverse drug interactions.

Infusion pumps include ambulatory infusion pumps, elastomeric pumps, syringe pumps, insulin pumps, patient-controlled analgesia pumps, and volumetric pumps. These technologies allow healthcare providers to deliver required amounts of medication or fluids while supporting treatment outside traditional hospital settings.

Needleless connectors are another important technology area. These devices can reduce the risk of bacterial contamination and needlestick injuries while supporting safer intravenous therapy. They can also help reduce healthcare-associated bloodstream infections.

Connected and intelligent infusion systems are becoming increasingly important. In April 2024, Baxter received U.S. FDA clearance for its Novum IQ large volume infusion pump and Dose IQ safety software, supporting connected and intelligent infusion therapy. In April 2025, ICU Medical received FDA clearance for additions to its infusion pump portfolio, including the Plum Solo single-channel and updated Plum Duo dual-channel precision IV pumps.

Market Segmentation & Performance

• Based on product, infusion pumps accounted for the largest market share, representing 51.50% of revenue in 2024. The strong position of infusion pumps is associated with their broad use in delivering medications, nutrition, and other fluids in controlled quantities. The product category includes ambulatory infusion pumps, elastomeric pumps, syringe pumps, insulin pumps, patient-controlled analgesia pumps, and volumetric pumps.
• Needleless connectors are anticipated to register the fastest CAGR because of their safety benefits and ability to reduce contamination and needlestick risks.
• By application, anti-infective therapy held the largest market share at 26.94% in 2024. Home-based administration of antibiotics and antivirals is increasingly used for conditions requiring prolonged intravenous treatment, including sepsis, osteomyelitis, and complicated urinary tract infections. Portable infusion pumps and catheter-based delivery systems support this application.
• Chemotherapy is expected to register the fastest CAGR from 2025 to 2033. The growth is supported by the increasing prevalence of cancer and demand for convenient treatment options that reduce frequent hospital visits. Enteral nutrition, parenteral nutrition, endocrinology, hydration therapy, specialty pharmaceuticals, and other applications also contribute to market demand.

Looking for more specific insights? Customize this report to suite your business needs

Regional Insights

The report focuses specifically on the U.S. market, where demand is supported by demographic changes, chronic disease prevalence, healthcare infrastructure, and increasing adoption of home-based care. The growing population aged 65 and older is an important factor because aging is associated with higher risks of infections and chronic conditions.

The U.S. healthcare system is also seeing increased adoption of home infusion as providers and payers seek to reduce hospital stays and optimize healthcare resources. The combination of improved infusion equipment, reimbursement policies, regulatory standards, and patient demand is supporting expansion across the country.

The market is described as fragmented, with multiple medical device manufacturers, infusion service providers, and healthcare solution companies competing across products and services. Partnerships between healthcare providers and technology companies are also supporting the integration of infusion pump systems with software platforms.

Key Market Players

Key companies operating in the U.S. home infusion therapy market include B. Braun Melsungen, Baxter International, Caesarea Medical Electronics Ltd., CareFusion, Fresenius Kabi, ICU Medical, JMS CO., LTD., Smiths Medical, Inc., Terumo Corporation, Coram LLC, Option Care Enterprises, Inc., BioScrip, Inc., BriovaRx Infusion Services, and Paragon Healthcare.

Companies are focusing on product development, partnerships, portfolio expansion, and improved access to home-based infusion services. Recent industry activity includes Baxter's injectable pharmaceutical product launches in the U.S. and the 2024 collaboration between ICU Medical and Otsuka Pharmaceutical Factory to enhance IV solutions and complementary infusion products in North America.

Latest Related Report Explores :

• Home Infusion Therapy Market (2026 - 2033)
• Home Healthcare Market (2026 - 2033)
• Smart Home Market (2026 - 2033)
• Home Insecticides Market (2026 - 2033)

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.